Ypsomed is the leading independent developer and manufacturer of user-friendly self-injection systems.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored self-care solutions to meet specific needs.
The company’s proven track record attests to its pioneering portfolio of pens, autoinjectors, and wearable devices for pharmaceutical applications.
Complete with best-in-class features and fully integrated with digital health services, Ypsomed’s solutions make therapy easier and contribute towards improving the quality of life for millions of people with chronic conditions.
Ypsomed’s self-injection products offer speed, reliability and versatility. Each product helps support development and customer project risk mitigation, while being completely scalable across the whole clinical chain, from early trial stages all the way through to commercial launch.
With a fully comprehensive product portfolio that is leading the market, Ypsomed’s offerings include YpsoMate and UnoPen.
Our modular platforms are thoroughly developed and tested, as well as validated through designs, pre-approved parameters, and a proven industrial manufacturing infrastructure. This promotes trust for our customers and a tried and tested foundation that saves time and leads products to market faster and more effectively.
Ypsomed platforms are designed for a wide variety of drug formulations for different viscosities and fill volumes. This flexibility is inherently built and allows for customisation without changing the main device.
Ypsomed has been a trusted self-injection device supplying partner to our pharmaceutical customers for more than 40 years. Over the last two decades, we have seen our product offerings evolve from cartridge-based peptide therapies for pens to also include syringe-based autoinjector therapies that answer the special needs of pharmaceutical companies and patients for antibody-based treatments.
While Ypsomed strives to be a leader in self-injection devices, we partner with these key suppliers to ensure that the delivery of the drug–device combination product is prompt, on time and meets the required needs of companies and patients.
Through strategic partnerships, our customers in the pharmaceutical industry benefit from top-quality solutions that reduce costs and reduce timelines for each drug product phase.
Ypsomed offers more than manufactured drug delivery products; we infuse our expertise into our solutions, optimise device platforms for patients and drugs, and provide global scalability with a goal towards ongoing and sustainable manufacturing excellence.
From clinical trial stages all through to full-scale commercial production, we instil confidence in our customers and offer unmatched quality that helps us build trusted partnerships.
All key manufacturing processes are performed in-house, and these range from tool design and manufacturing to injection moulding and assembly. Our internal manufacturing operations are located at our head offices in Burgdorf, Switzerland, and facilitate high efficiency and seamless communication among teams for the best possible results. Fast communication, prompt feedback and full control help ensure products are delivered on time and to the highest standards.
Our services expand beyond drug delivery devices to also include built-in and optional services for every developmental stage. From human factors and regulatory expertise to sustainability and testing, we help minimise risk and support long-term market success through reducing challenges and driving forward customer launch.
Our services help accelerate the full lifecycle of combination product development, which includes early planning, customisation, industrialisation, launch and post-market assistance.
There is seamless collaboration among professionals with expertise in design, usability, quality, regulatory, and testing, which helps advance decision-making, better communication, and harmonious alignment from design to delivery.
Ypsomed is committed to a long-term corporate sustainability strategy, and its ethics revolve around responsibility towards our employees, our partners, society and the environment.
The increased use of plastics associated with the growing adoption of pre-filled self-injection systems has an environmental impact. In response, Ypsomed has established responsibility & engagement as a fully integrated pillar of its corporate strategy.
Our commitment to sustainability is multifaceted and encompasses the company’s NetZero Program, our roadmap to net zero emissions by 2040, as well as our ecodesign ethics that see eco-friendly practices for our product design cycles.
Looking ahead, our next generation of platform products will mark a major shift towards sustainable self-injection device manufacturing that is responsible and sensitive to the environment. Our award-winning autoinjector, YpsoLoop, which was launched in October 2025, allows for material recovery through automated disassembly and recycling.
In 1984, brothers Willy and Peter Michel founded Disetronic in Burgdorf, Switzerland. The company was the first to introduce a micro insulin pump to the market and, along with its infusion systems, also specialised in injection systems.
In 2003, co-founder and majority shareholder Willy Michel sold Disetronic’s infusion part of the business to Roche, but kept the injection business, which was how Ypsomed was born. Since then, Ypsomed has grown to be successful in the pharmaceutical market.
Ypsomed is headquartered in Burgdorf, Switzerland, with various manufacturing facilities around the world. The company employs more than 2,000 people who are committed to making self-care easier and more sustainable.
In this article, Thomas Fontanellaz, Reto Jost, and Andreas Schneider, all at Ypsomed, discuss how the company is addressing the growing need for subcutaneous injections that accommodate higher volumes and viscosities.
Andreas Schneider and Jakob Lange of Ypsomed consider the subcutaneous administration of larger volumes of biopharmaceuticals in the pharmaceutical industry.
Lorenzo Biasio and Gloria Skibba, both at Ypsomed, discuss the integration of the company’s Net Zero Program into its self-injection platforms and explain how YpsoMate 1 and 2.25 mL autoinjectors have been redesigned to achieve a lower carbon footprint.
Thomas Blaser of Ypsomed and Dr Maëlle Douaire of BD explore how drug viscosity, autoinjectors and syringes affect the administration of injectable therapies, demonstrating the results of a study evaluating combined autoinjectors and syringes from the two companies that provide efficient and smooth delivery of high-dose therapies.
Philipp Richard of Ypsomed scrutinises the efficient production of self-injection devices in the pharma industry and describes Ypsomed’s own platforms for developing these devices, highlighting the need to be adaptable and resilient to the rapidly evolving world of drug development.
Reto Jost and Daniel Käser of Ypsomed detail how the company is approaching wearable injector design with YpsoDose and achieving large-volume requirements, consistent dosing and low residual waste.
Stefanie Stark and Sandra Schaerer-Lickova of Ypsomed highlight how regulatory strategy enables ideas to become solutions, supports development through the product lifecycle and helps ensure that patients worldwide obtain safe and timely access.
Ypsomed Holding AG (SIX: YPSN) has successfully completed the sale of its Ypsomed Diabetes Care business to TecMed AG.
The US Food and Drug Administration (FDA) has granted 510(k) clearance for SmartPilot, a digital connectivity add-on developed by Ypsomed.
At its Capital Markets Day at Ypsomed’s manufacturing plant in Schwerin, Germany, on Monday, September 29, 2025, Ypsomed announced its key strategic priorities and mid-term ambition.
Ypsomed celebrated the topping-out ceremony for its second plant in Schwerin with over 200 guests from politics, business, and the construction trade.
Ypsomed will establish its first manufacturing facility in the US. The company has selected Holly Springs in Wake County, North Carolina, as the location, and will invest around CHF200m in a first phase.
Ypsomed launches YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 ml and 2ml platform versions enable material recovery through a design enabling automated disassembly and efficient recycling, while offering the convenience of a pre-filled, two-step autoinjector.
Ypsomed (SIX: YPSN) continued on its growth trajectory in the first half of the 2025/26 financial year, as the Delivery Systems business reached CHF266.6m of sales.
Romaco has developed the first Siebler StripTabs™ line for Indian contract manufacturer ANKUR Drugs and Pharma Ltd. The system's innovative design was specially created for the production and packaging of pharmaceutical film tablets. For the first time, this novel drug delivery sy
The Contite measuring cell proves its unbeatable advantages At customers’ premises, our instruments are actually on the test bench day by day – Deltapilot S FMB70, however, has recently passed a special test. Developed for the requirements of the pharmaceutical and hygiene industry it s
Since product quality is often affected by the environmental conditions in a clean room, it is essential to monitor critical parameters such as particle concentration,temperature, differential pressure and humidity. In addition air flow (speed and direction) and door interlocking must be contro
YpsoLoop is a paradigm-shifting circular solution. It is a convenient, pre-filled, two-step, single-use device that enables material recovery through automated disassembly and efficient recycling.
YpsoFlow is a spring-driven, pre-filled pen platform for GLP-1 and peptide therapies, which delivers doses of up to 0.80mL with a low-force mechanism and audible dose feedback.
Larger volume capability, delivering doses of up to 1.0mL – five times more than comparable models with similar handling mechanisms – making it ideal for higher-dose therapies.
The YpsoMate autoinjector is an automated injection device for 1mL pre-filled glass or polymer syringes intended for all patient groups.
YpsoMate 2.25 and YpsoMate 2.25 Pro autoinjectors are automated injection devices for 2.25 mL pre-filled glass or polymer syringes and intended for all patient groups.
YpsoMate 5.5 autoinjector is an automated injection device for 5.5mL pre-filled glass syringes, intended for all patient groups.
The UnoPen is an easy-to-use variable-dose pen designed for insulin, GLP-1, and other multidose therapies, delivering familiar handling that supports strong patient acceptance.
YpsoDose is the pre-filled, ready-to-use patch injector intended for subcutaneous delivery of volumes up to 10mL.
High-tech manufacturing of our flagship pen platform UnoPen, the intuitive dial & dose pre-filled pen.
The pre-filled, ready-to-use patch injector is designed for subcutaneous delivery of volumes up to 10mL.
High-tech manufacturing of our flagship autoinjector platform YpsoMate, the two-step intuitive autoinjector.
The award-winning autoinjector uniting sustainability and patient convenience.
An overview of our products, services and innovations. Ypsomed is the reliable partner for self-care solutions.
The 5.5ml large volume autoinjector takes handheld self-injection beyond volumes of 2.0ml.
